Back

Circulating PD-1hi CXCR5- and CXCR5+ CD4 T cells are elevated in patients with newly diagnosed Giant Cell Arteritis and predict relapse

Monjo-Henry, I.; Nieto-Carvalhal, B.; Uyaguari, M.; Garcia-Carazo, S.; Balsa, A.; de Miguel, E.; Miranda-Carus, M.-E.

2024-05-14 immunology
10.1101/2024.05.12.593745 bioRxiv
Show abstract

BACKGROUNDGiant cell arteritis (GCA) is a large/medium-vessel granulomatous vasculitis, and the PD-1/PD-L1 coinhibitory pathway seems to be implicated in its pathogenesis. CD4 T cells expressing high PD-1 levels, CD4+CXCR5-PD-1hi peripheral helper (Tph) and CD4+CXCR5+PD-1hi follicular helper T cells (Tfh), are key mediators of autoimmunity. Their frequencies are elevated in the peripheral blood of subjects with several autoimmune conditions but have not been investigated in GCA. Our objective was to study the frequency of circulating Tph (cTph) and Tfh (cTfh) in patients with newly diagnosed GCA (nGCA). METHODSProspective, non-interventional study on consecutive patients referred to our ultrasound GCA fast-track clinic over a period of 24 months. Peripheral blood was drawn immediately upon initial diagnosis. For each patient, an age and gender-matched healthy control (HC) was included. PBMCs isolated by Ficoll-Hypaque were examined by cytometry. Patients were subsequently treated with standard therapy according to the updated 2018 EULAR recommendations. RESULTS65 nGCA patients were included. As compared with HC, nGCA patients presented at baseline with an increased frequency of cTph and cTfh cells. Among the 46 patients who could be followed up for 12 months, 19 experienced a relapse. The baseline frequency of cTph and cTfh cells had been significantly lower in patients who relapsed as compared with those who did not. A cTph cell frequency <0.56 predicted relapse with a sensitivity of 90% and specificity of 93%. CONCLUSIONnGCA patients demonstrate increased baseline cTph and cTfh cell frequencies. Lower baseline proportions of cTph and cTfh cells associate with relapse.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
638 papers in training set
Top 0.6%
15.8%
2
Annals of the Rheumatic Diseases
36 papers in training set
Top 0.1%
13.6%
3
Journal of Autoimmunity
10 papers in training set
Top 0.1%
11.6%
4
Arthritis & Rheumatology
36 papers in training set
Top 0.1%
7.6%
5
PLOS ONE
5266 papers in training set
Top 23%
7.1%
50% of probability mass above
6
European Journal of Immunology
60 papers in training set
Top 0.3%
4.5%
7
Clinical Immunology
21 papers in training set
Top 0.1%
4.5%
8
RMD Open
14 papers in training set
Top 0.1%
2.6%
9
eLife
5828 papers in training set
Top 46%
2.0%
10
Scientific Reports
3612 papers in training set
Top 52%
1.8%
11
Journal of Cellular and Molecular Medicine
20 papers in training set
Top 0.3%
1.2%
12
Frontiers in Pediatrics
32 papers in training set
Top 0.7%
1.2%
13
Rheumatology
24 papers in training set
Top 0.3%
1.1%
14
The Journal of Infectious Diseases
202 papers in training set
Top 3%
1.1%
15
Orphanet Journal of Rare Diseases
21 papers in training set
Top 0.5%
1.1%
16
International Journal of Molecular Sciences
494 papers in training set
Top 13%
1.0%
17
Annals of Neurology
64 papers in training set
Top 2%
0.6%
18
Journal of Internal Medicine
12 papers in training set
Top 0.3%
0.6%
19
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%
20
Frontiers in Medicine
120 papers in training set
Top 5%
0.6%
21
BMC Neurology
14 papers in training set
Top 0.8%
0.6%
22
Cells
249 papers in training set
Top 8%
0.6%
23
Journal of Translational Medicine
57 papers in training set
Top 2%
0.6%
24
Immunity, Inflammation and Disease
10 papers in training set
Top 0.6%
0.5%
25
The Journal of Immunology
166 papers in training set
Top 3%
0.5%
26
Genes & Immunity
11 papers in training set
Top 0.3%
0.5%
27
The Lancet Rheumatology
11 papers in training set
Top 0.2%
0.5%
28
Journal of Clinical Immunology
14 papers in training set
Top 0.2%
0.5%
29
Journal of Neuroinflammation
61 papers in training set
Top 2%
0.5%